Archives: Agenda
WORKSHOP: Responsible AI in oncology clinical trials: Applying the AI rights initiative to recruitment, patient data, and patient trust
Concept: This interactive workshop introduces the AI Rights Initiative as a practical framework that sponsors, CROs, and recruitment vendors can use to evaluate AI systems used in oncology trials. Through a short panel discussion and facilitated table conversations, participants will explore how recruitment algorithms, digital tracking technologies, and patient data analytics intersect with patient rights and regulatory responsibilities
Takeaway: Attendees will leave with practical governance questions that can help organizations implement AI responsibly while maintaining patient trust in clinical research
END OF DAY 1 AND NETWORKING DRINKS
Signal Over Sprawl: Using Adaptive Randomization to Focus Early Oncology Development
Adaptive randomization can help conserve scarce patient data by increasing learning efficiency in early oncology trials. Its value depends on sponsors entering development with clear priorities around one or two target indications. Without that discipline, adaptive designs risk adding operational complexity to broad, unfocused programs without yielding a clean development signal. This presentation will explore adaptive randomization and its utility in:
- Conserving scarce patient data in early development
- Improving signal detection through intentional focus
- Rewarding discipline over broad exploratory ambition
Overview of the investor landscape to navigate and secure investment for oncology clinical trials
- Aligning clinical trials with today’s investment priorities
- Building investor value: From inflection points to unique positioning
- Strategic connections for oncology clinical trial funding
Afternoon refreshments and networking
The Critical Role of Pathologists and Molecular Technologies in Clinical Trial Success
- Overview of pathology and the expertise of pathologists in tissue evaluation and procurement for clinical trial success
- Overview of pathology and the expertise of pathologists in tissue evaluation and procurement for clinical trial success
- Best practices for tissue and liquid biopsy selection, handling, and quality assurance, including considerations for ctDNA and MRD testing.
- Case-based examples demonstrating optimal specimens for clinical trial enrollment, as well as common pitfalls in tissue and ctDNA/MRD workflows leading to case failures.
- How Natera harnesses real-world data from its commercial pipeline to accelerate clinical trial advancement and enrollment
The real reason trials fail isn’t recruitment… it’s design
- Why most oncology trial delays are designed in before the first patient is enrolled
- How Pharma, Biotech and CRO teams are using AI to eliminate amendments before they happen
- What it takes to build a protocol that actually works operationally, globally, and regulator-ready from day one
Planning and executing patient-centric clinical studies: Lessons learned from the WISDOM Study platform for personalized breast cancer screening
- Incorporating patient-centric strategies in trial designs to reduce patient burden
- Overview of new innovations that can be included in studies to increase patient centricity
- Adopting a patient-first mindset when designing trial protocols for patient-friendly studies
Oncology trials as a start-up: Identifying challenges and pain points to overcome and conduct effective oncology clinical trials
- Understanding the unique challenges biotechs face to reduce roadblocks and ensure clinical trial success
- Weighing up in-house capacity versus budget to ensure effective outsourcing decisions
- Working with limited resources to ensure regulatory compliance and minimize roadblocks